These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
5. Immune-based guidance of foscarnet treatment duration in a transplant recipient with ganciclovir-resistant cytomegalovirus infection. Mihm J; Leyking S; Dirks J; Smola S; Fliser D; Sester U; Sester M; Wilkens H; Rissland J J Clin Virol; 2016 Sep; 82():5-8. PubMed ID: 27389910 [TBL] [Abstract][Full Text] [Related]
6. Clinical impact of ganciclovir-resistant cytomegalovirus infections in solid organ transplant patients. Boivin G; Goyette N; Gilbert C; Humar A; Covington E Transpl Infect Dis; 2005; 7(3-4):166-70. PubMed ID: 16390409 [TBL] [Abstract][Full Text] [Related]
7. Subtherapeutic ganciclovir (GCV) levels and GCV-resistant cytomegalovirus in lung transplant recipients. Gagermeier JP; Rusinak JD; Lurain NS; Alex CG; Dilling DF; Wigfield CH; Love RB Transpl Infect Dis; 2014 Dec; 16(6):941-50. PubMed ID: 25491023 [TBL] [Abstract][Full Text] [Related]
8. Trip to immunity: resistant cytomegalovirus infection in a lung transplant recipient. Kneidinger N; Giessen C; von Wulffen W; Milger K; Schramm R; Jäger G; Nitschko H; Striebinger H; Behr J; Neurohr C Int J Infect Dis; 2014 Nov; 28():140-2. PubMed ID: 25267276 [TBL] [Abstract][Full Text] [Related]
9. Ganciclovir-resistant cytomegalovirus infection in solid organ transplant recipients: a single-center retrospective cohort study. Young PG; Rubin J; Angarone M; Flaherty J; Penugonda S; Stosor V; Ison MG Transpl Infect Dis; 2016 Jun; 18(3):390-5. PubMed ID: 27037651 [TBL] [Abstract][Full Text] [Related]
10. Leflunomide as part of the treatment for multidrug-resistant cytomegalovirus disease after lung transplantation: case report and review of the literature. Verkaik NJ; Hoek RA; van Bergeijk H; van Hal PT; Schipper ME; Pas SD; Beersma MF; Boucher CA; Jedema I; Falkenburg F; Hoogsteden HC; van den Blink B; Murk JL Transpl Infect Dis; 2013 Dec; 15(6):E243-9. PubMed ID: 24298985 [TBL] [Abstract][Full Text] [Related]
11. Combination antiviral therapy for ganciclovir-resistant cytomegalovirus infection in solid-organ transplant recipients. Mylonakis E; Kallas WM; Fishman JA Clin Infect Dis; 2002 May; 34(10):1337-41. PubMed ID: 11981729 [TBL] [Abstract][Full Text] [Related]
12. Persistent Primary Cytomegalovirus Infection After Deceased Donor Kidney Transplant: Ganciclovir Susceptibility of Human Cytomegalovirus With UL97 D605E Mutation: A Case Report. Nawashiro Y; Shiraki K; Yamamoto S; Takizawa K; Sasada Y; Suehiro M; Miura K; Hattori M; Daikoku T; Hisano M Transplant Proc; 2018 Dec; 50(10):3932-3936. PubMed ID: 30577289 [TBL] [Abstract][Full Text] [Related]
13. Viral monitoring and successful treatment of a ganciclovir-resistant cytomegalovirus infection in a heart transplant recipient. García-Martínez J; Folgueira L; Delgado R; Hernando S; Prieto C; Aguado JM; Otero JR Transpl Infect Dis; 2008 Apr; 10(2):123-8. PubMed ID: 17605746 [TBL] [Abstract][Full Text] [Related]
14. [Foscarnet therapy for ganciclovir-refractory cytomegalovirus hepatitis in a patient who underwent bone marrow transplantation from an unrelated donor]. Fujisaki T; Gondo H; Uchida N; Matsuo I; Takenaka K; Tanimoto K; Otsuka T; Minematsu T; Minamishima Y; Niho Y Rinsho Ketsueki; 1997 Feb; 38(2):142-5. PubMed ID: 9059069 [TBL] [Abstract][Full Text] [Related]
15. Ganciclovir-resistant cytomegalovirus encephalitis in a bone marrow transplant recipient. Julin JE; van Burik JH; Krivit W; Webb C; Holman CJ; Clark HB; Balfour HH Transpl Infect Dis; 2002 Dec; 4(4):201-6. PubMed ID: 12535263 [TBL] [Abstract][Full Text] [Related]
16. Incidence and outcomes of ganciclovir-resistant cytomegalovirus infections in 1244 kidney transplant recipients. Myhre HA; Haug Dorenberg D; Kristiansen KI; Rollag H; Leivestad T; Asberg A; Hartmann A Transplantation; 2011 Jul; 92(2):217-23. PubMed ID: 21685829 [TBL] [Abstract][Full Text] [Related]
17. Emergence of letermovir resistance in a lung transplant recipient with ganciclovir-resistant cytomegalovirus infection. Cherrier L; Nasar A; Goodlet KJ; Nailor MD; Tokman S; Chou S Am J Transplant; 2018 Dec; 18(12):3060-3064. PubMed ID: 30286286 [TBL] [Abstract][Full Text] [Related]
18. Safety and efficacy of prolonged cytomegalovirus prophylaxis with intravenous ganciclovir in pediatric and young adult lung transplant recipients. Spivey JF; Singleton D; Sweet S; Storch GA; Hayashi RJ; Huddleston CB; Danziger-Isakov LA Pediatr Transplant; 2007 May; 11(3):312-8. PubMed ID: 17430489 [TBL] [Abstract][Full Text] [Related]
19. Letermovir successfully used for secondary prophylaxis in a heart transplant recipient with ganciclovir-resistant cytomegalovirus syndrome (UL97 mutation). Chong PP; Teiber D; Prokesch BC; Arasaratnam RJ; Peltz M; Drazner MH; Garg S Transpl Infect Dis; 2018 Oct; 20(5):e12965. PubMed ID: 29989279 [TBL] [Abstract][Full Text] [Related]
20. Resistance to combined ganciclovir and foscarnet therapy in a liver transplant recipient with possible dual-strain cytomegalovirus coinfection. Rodriguez J; Casper K; Smallwood G; Stieber A; Fasola C; Lehneman J; Heffron T Liver Transpl; 2007 Oct; 13(10):1396-400. PubMed ID: 17902124 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]